We are live on ! Find out more
CHNA

Loncar China BioPharma ETF
CHNA

Delisted

CHNA was delisted on the 20th of October, 2023.

Back to rankings

0 hedge funds and large institutions have $0 invested in Loncar China BioPharma ETF in 2023 Q4 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 4 → 0 (-4)

100% less capital invested

Capital invested by funds: $550K → $0 (-$550K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 4

Holders
–
Holders Change
-4
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Jane Street
Jane Street
New York
-$276K
2
GS
GTS Securities
New York
-$267K
3
BBPWM
Blue Bell Private Wealth Management
Pennsylvania
-$4.39K
4
Morgan Stanley
Morgan Stanley
New York
-$2.68K
Name Holding Trade Value Shares
Change 		Change in
Stake
Jane Street
1
Jane Street
New York
– -$276K -19,335 Closed
GS
2
GTS Securities
New York
– -$267K -18,727 Closed
BBPWM
3
Blue Bell Private Wealth Management
Pennsylvania
– -$4.39K -308 Closed
Morgan Stanley
4
Morgan Stanley
New York
– -$2.68K -188 Closed

CHNA Hedge Fund Activity: Q4 2023 in Review

0 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Loncar China BioPharma ETF (CHNA) for Q4 2023, worth a combined $0 — down 100% from $550K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of CHNA and 0 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Jane Street, exiting entirely with an estimated $276K sold.

  • 0 institutional investors held Loncar China BioPharma ETF (CHNA) as of Q4 2023, down from 4 in Q3 2023.
  • Funds reported $0 of Loncar China BioPharma ETF stock for Q4 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Loncar China BioPharma ETF positions in Q4 2023 and 4 closed out, a net change of -4 holders.
  • The largest Loncar China BioPharma ETF seller in Q4 2023 was Jane Street, an estimated $276K sold.

Based on aggregated 13F filings for Q4 2023.